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Resistance to other xenobiotics. Five strains of serotype A heteroresistant at >32 µg/ml 3 FLC and five strains heteroresistant at < 8 µg/ml (Table 4 (0.8 and 1.6 µg/ml), and L-canavanine (30 µg/ml).Unless specified, all compounds were 10 obtained from Sigma (Sigma-Aldrich, St. Louis, MO). Cells of the 10 strains were 11 spotted on YPD agar and incubated at 30, 37, and 40°C for 72 h to compare their growth. 12 Virulence study. All animal studies were approved by the institutional animal care and 13 use committee. To compare the virulence among different strains, a murine model of 14 pulmonary cryptococcosis was established in female BALB/c mice (weight, 20 g) by 15 intranasal inoculation of serotype A strains. Five strains heteroresistant at > 32 µg/ml and 16 five strains heteroresistant at ≤ 8 µg/ml FLC, which had been used for the comparison of 17 xenobiotic tolerance, were used in this study. The strains used were also comparable in 18 the production of capsule, melanin and urease at 37 o C. The growth rate of these strains at 19 37 o C, measured by the colony size (100-150 colonies/plate) on YPD agar after 72 h 20 incubation, was similar except for NIH38 (heteroresistant at 4 µg/ml) which showed 21 slightly smaller colonies. Although the strain NIH38 had a slower growth rate at 37 o C, it 22 was chosen along with the strain NIH404 to represent the group which manifested 23 heteroresistance at 4 µg/ml because of their higher cell viability compared to other strains 1 in the same group. Mice were anesthetized with isoflurane and a 20 µl droplet containing 2 5 x 10 7 cells was placed on the nares of each mouse while the diaphragm was 3 compressed. The diaphragm was released to allow each mouse to inhale the droplet. Ten 4 animals were used for each strain. The survival of mice was recorded daily for the total of 5 60 days. 6 FLC therapy for experimental animals. For the FLC efficacy study, a selected group 7 of isolates with different level of heteroresistance were tested in mice by using the 8 systemic model of cryptococcosis. The mice were challenged intravenously with 9 inoculums ranging between 5 x 10 4 to 5 x 10 6 CFU/mouse. FLC was administered 10 intraperitoneally at a concentration of 10 mg/kg/day. Treatment was begun 24 h after 11 infection and was continued for 14 days. The mice were observed through day 40 and 12 deaths were recorded daily. Two mice in each group were used for the analysis of fungal 13 burden in the brain at indicated days post-infection. Mice were euthanized by CO 2 -14 induced asphyxia, and the number of viable CFU was determined by quantitative plating 15 of the brain homogenates on YPD agar plates with or without FLC at 8, 16 or 32 µg/ml. 16 There were 8 mice per group in the survival study and two mice each per group in the 17 analysis of fungal tissue burden. 18
Statistics. Survival data from the animal experiments were analyzed using the log-rank 19
test. An unpaired t test was used in evaluating the CFU from the tissue burden studies. A 20
Results
1
Heteroresistance to FLC in C. neoformans is intrinsic. The serotype A reference strain 2 H99, whose genome has been sequenced (http://www.broad.mit.edu/annotation/genome/ 3 cryptococcus neoformans/MultiHome.html), was used in our study to establish the 4 representative pattern of heteroresistance (Fig. 1) . While no inhibition in the growth of 5 H99 cells was observed at 16 µg/ml FLC, only 0.3 to 0.6 percent of the cells grew as an 6 initial minor subpolulation at 32 µg/ml FLC within 72 hours. We designated the level of 7 FLC heteroresistance in H99 as 32 µg/ml. When the cells grown at 32 µg/ml FLC were 8 transferred to fresh YPD agar containing 32 µg/ml FLC, all the cells grew. Upon transfer 9 to media containing 64 µg/ml FLC, however, only 0.3-0.6% grew again and formed 10 colonies within 72 h. Among these cells, now resistant at 64 µg/ml FLC, only 25% of the 11 subpopulation could grow on agar media containing 128 µg/ml FLC. When subjected to 12 repeated transfer in drug free broth media, the cells of these highly resistant subclones 13 reverted back to a frequency of between 0.3 and 0.6% on 32 µg/ml FLC. 14 To our surprise, all 130 strains of C. neoformans that had been isolated before 1979 15 (Tables S1, S2) , at least 10 to 20 years prior to the advent of azole therapy, manifested 16 heteroresistance at specific concentrations of FLC (Tables 1 and 2 ). Fifty seven strains 17 (51 of serotype A and 6 of serotype D) exhibited subpopulations resistant to FLC at a 18 concentration of >16 µg/ml; the remaining 73 strains were more susceptible and 19 produced heteroresistant colonies at a FLC concentration of < 8 µg/ml (Tables 1 and 2) . 20
We also analyzed 16 clinical strains isolated from AIDS patients undergoing FLC 21 maintenance therapy between 1990-2000 and had been identified as FLC resistant by the 22 conventional microdilution test (MIC ranges 16-64 µg/ml) for heteroresistance. 23
Interestingly, all these strains also displayed heteroresistance at FLC levels ranging from 1 16 to128 µg/ml (Table 3) . Furthermore, all the strains tested showed resistant 2 subpopulations at a frequency of 0.3 to 10% at each specified drug concentration. These 3 data indicate that heteroresistance to FLC in C. neoformans is intrinsic and the resistance 4 in the majority of FLC resistant isolates recovered from AIDS patients during FLC 5 maintenance therapy is attributed to heteroresistance. 6
Stepwise increase of FLC resistant levels in resistant subpopulations. 7
A minor subpopulation in each strain capable of growth on YPD at a certain 8 concentration of FLC yielded homogenous resistant colonies when subcultured on media 9
with the same concentration of FLC. This indicated that once the subpopulations had 10 adapted to a certain concentration of FLC, the majority of cells in the clonal population 11 became resistant to the drug at that concentration. The subpopulations of strains 12 heteroresistant at FLC concentration of 4 to 16 µg/ml were exposed in a stepwise manner 13 to increasing concentrations of up to 64 µg/ml. All such isolates successfully acquired 14 resistance at 64 µg/ml. The clones highly resistant to FLC (initially selected on 32-128 15 µg/ml) could tolerate FLC concentrations up to 256 µg/ml. This indicated that the level 16 of FLC resistance in the heteroresistant subpopulations could be increased in a stepwise 17 manner and the maximum concentration of FLC to which each strain could adapt varied 18 depending on the strain. 19
Reversibility of resistance in vitro.
We demonstrated that the FLC resistance levels of 20 the subpopulations for all C. neoformans strains could be increased in a stepwise manner 21 by exposing them to higher concentrations of the drug. We randomly selected 57 strains 22 with original levels of heteroresistance beteween 16-128 µg/ml FLC that had been 23 isolated before 1979 and all 16 FLC resistant strains isolated from AIDS patients 1 undergoing FLC maintenance therapy between 1990-2000 to study the reversibility of 2 resistance. Clones from the stepwise selection at higher drug concentration (64-128 3 µg/ml) of the 73 strains were repeatedly transferred in drug-free YPD broth. Cultures 4 were periodically plated on YPD agar with 16-128 µg/ml FLC and evaluated for the 5 frequency of the population that formed colonies on media at the given drug 6 concentration. All strains isolated before 1979 and the 16 strains, except for one, isolated 7 from AIDS patients with recurrent cryptococcosis during FLC maintenance therapy lost 8 resistance at 64-128 µg/ml and reverted back to the original level of heteroresistance by 9 day 45. Interestingly, based on the duration required for reversion regardless of their 10 original level of heteroresistance, we were able to classify these strains into four different 11
classes. The first class reverted abruptly after only three transfers while the remaining 12 three classes required at least 16, 26 and 45 transfers, respectively. One of the 16 AIDS 13 isolates, once it acquired resistance to FLC, showed no signs of reversion even by day 45. 14 To show the reversion pattern of the four classes we selected four strains of serotype A 15 that manifested heteroresistance at 32 µg/ml and analyzed the reversibility of their 16 resistance after selecting subpopulations that could withstand 64 µg/ml FLC. Fig. 2  17 shows reversibility of four strains representing the four classes among serotype A strains. 18
Subclones resistant at 64 µg/ml FLC were isolated and transferred daily into new YPD 19 drug-free broth for 45 days. The NIH157 strain which reverted after three transfers 20 yielded a 10% subpopulation that grew at 32 µg/ml FLC and represented the first class. was compared with that of H99 R64 , a strain resistant to 64 µg/ml FLC generated in vitro 7
by exposing H99 cells to 64 µg/ml FLC. Upon exposure of H99 cells to 64 µg/ml FLC, 8 the ergosterol content in the cells was greatly reduced and its major sterol was eburicol 9 which is consistent with the fact that FLC blocks the C14 demethylation step (31) ( 
H99
R64 cells in drug-free media, the eburicol and ergost-7-enol levels were restored to 17 those of H99 (data not shown). These results indicated that there were no significant 18 differences in the sterol profiles between the isolates in the presence or absence of FLC. 
R64 was two fold higher than that of the wild-type strain (Fig. 4) . A two-fold increase 20 in the expression of AFR1 in strain H99
R64 confirms the role of AFR1 in FLC resistance. 21
Relationship between FLC heteroresistance and resistance to other xenobiotics. In 22 order to determine the relationship between heteroresistance to FLC and resistance to 23 other xenobiotics, we chose five highly resistant strains (≥ 32 µg/ml) and 5 strains 1 expressing heteroresistance at a low concentration of FLC (≤ 8 µg/ml) ( Table 4 highly FLC-heteroresistant strains (≥ 32 µg/ml) generally exhibited a higher resistance to 13 the four compounds when compared to the strains with heteroresistance at a lower 14 concentration (≤ 8 µg/ml) of FLC (Table 5) . It is clear, however, that the tolerance to 15 these xenobiotics can not be defined as heteroresistance since the tolerance did not 16 increase upon serial passages in higher concentrations of the inhibitors and it could not be 17 reversed in their absence (data not shown). To evaluate the efficacy of FLC therapy, ten mice each in three groups were inoculated 5 intravenously with strains H99, NIH136 and NIH38 (MIC values of FLC by E-test 24, 2 6 and 1 µg/ml, respectively) expressing FLC heteroresistance levels of 32, 8 and 4 µg/ml, 7
respectively. The mice were treated with FLC 10 mg/kg/day for two weeks starting 24h 8 after infection. The control mice infected with H99 received only vehicle for two weeks. 9
The inoculum of H99 was 100 fold less than the other strains since H99 is significantly 10 more virulent. H99 caused 100% mortality in both the control (no treatment) and the FLC 11 treated group by day 17 with a marginal difference in the survival rate (Fig. 6A) . In the 12 groups infected with NIH136 and NIH38, however, FLC-treated mice survived 13 considerably longer than those of the untreated controls ( Fig. 6B and C ; P < 0.01). The 14 FLC therapy efficacy was most pronounced in mice infected with NIH38 that exhibited 15 heteroresistance at the lowest level (4 µg/ml). While 100 % of the control mice died by 16 day 29, only 50 % of the mice treated with FLC had died by day 40, the termination date 17 of the experiment (Fig. 6C) . To investigate the progression of infection and the 18 possibility of FLC derived enrichment in resistant subpopulations, fungal burdens in the 19 brain were determined. In the H99 (heteroresistant at 32 µg/ml) infected animals, there 20 were no clear differences in the brain fungal burdens between treated and control 21 subgroups (Fig. 7A) . In contrast, in the groups infected with the strains NIH136 22 (heteroresistance at 8 µg/ml) and NIH38 (heteroresistance at 4 µg/ml), fungal burdens 23 on August 29, 2017 by guest http://aac.asm.org/ Downloaded from were lower, as expected, in the FLC-treated animals compared to control mice (1.5 and 2 1 logs less in NIH136 and NIH38-infected mice, respectively) ( Fig. 7B and C) . However, 2 when the brain homogenate of the same animal was plated onto YPD plates containing 3 FLC, the number of resistant subpopulations was significantly higher in treated mice 4 compared to control mice. No difference in the proportion of the FLC resistance 5 subpopulation at 32 µg/ml was observed between the FLC treated and untreated H99 6 infected mice (Fig. 8A) . Since the strain NIH136 expressed heteroresistance at 8 µg/ml, 7 the proportion of FLC resistant subpopulation was analyzed on YPD containing 8 µg/ml 8 FLC. In the group infected with this strain, the frequency of the resistant subpopulation at 9 8 µg/ml of FLC increased from 0.3% on day 0 (inoculum) to 1.32% on day 15 in the 10 brain of treated mice and resistant subclones decreased from 0.3 to 0.19% in untreated 11 animals (Fig. 8B) . Interestingly, in animals infected with NIH38 (heteroresistant at 4 12 µg/ml), the subpopulation resistant at 8 µg/ml was found only in FLC treated mice that 13 increased from 0% (inoculum) to 3.57% by day 12 of treatment ( Fig. 8C) . These results 14 demonstrate that FLC treatment has little efficacy in the cases of infection caused by 15 strains expressing high heteroresistance levels (≥ 32 µg/ml). However, Long-term usage of FLC, the most widely used triazole drug, for the management of 3 cryptococcosis in AIDS patients, led to the emergence of FLC resistant strains (2, 4, 19,  4 33, 50). However, the isolation of resistant strains during long term azole therapy in 5 cryptococcosis has been much less frequently reported compared to other pathogenic 6 yeasts such as Candida species (7, 15, 41, 47, 48). As a result, relatively little attention 7 has been paid to the mechanism of azole resistance in C. neoformans. 8
When we first described the heteroresistance to azoles in C. neoformans (30), we 9 excluded the possibility of mutations in ergosterol biosynthetic genes or efflux pumps 10 since the frequency of resistant subpopulations was too high and all resistant clones 11 reverted back to the original susceptible phenotype. There was, however, a question 12 whether this type of unusual resistance to azoles was intrinsic or acquired through 13 exposure to azole drugs since they were isolated during the 1990s. In the present study, 14 we found FLC heteroresistance in all strains of C. neoformans isolated long before the 15 advent of azole drugs indicating that heteroresistance in this pathogen is intrinsic. (Tables 1 and 2) . It is also significant that the strains that exhibited a higher level of heteroresistance were 3 also more virulent in the animal model compared to strains that expressed a lower level 4 of heteroresistance. 5
A previous report on the emergence of "mutant" clones resistant to FLC in 21 C. 6 neoformans strains (54) appears to suggest that the rate of "mutation" may actually 7
represent the rate at which subpopulations express heteroresistance at 8 µg/ml FLC. Unlike H99, the afr1∆ strain exhibited heteroresistance at 1 µg/ml FLC which could only 23 be raised to 8 µg/ml FLC by stepwise adaptation. Furthermore, 26 daily transfers in drug-1 free media were required for the afr1∆ R8 subclones to revert back to the original 2 phenotype (heteroresistance at 1 µg/ml). These results indicated that AFR1 plays a major 3 role in FLC resistance without being involved in the mechanism of heteroresistance. Heterogeneous resistance can also develop in Candida albicans after only short exposures 22 to FLC, both in vitro and in vivo (10, 29, 32) . This rapid development of resistance has 23 been observed in C. albicans strains that cause disseminated infection in patients after 1 receiving bone marrow transplantation (27, 29) . In these clinical isolates, resistance to the 2 azole drugs was transient, as the strains became susceptible after serial transfers in the 3 absence of drug (27, 28) . A recent study by Selmecki et al (42) revealed an association of 4 aneuploidy and azole resistance in C. albicans. In the resistant strains, presence of extra 5 left arms of chromosome 5 was detected and gain and loss of this isochromosome was 6 strongly associated with increased and decreased azole resistance. It remains to be 7 elucidated whether a similar mechanism is responsible for the heteroresistance in C. 8
neoformans. 9
In conclusion, FLC heteroresistance was found to be universal in C. neoformans strains 10 tested and represents a novel intrinsic adaptive mechanism for survival under the azole 11 stress. Not all strains heteroresistant at high levels of FLC were hypervirulent but all 12 highly virulent strains manifested heteroresistance at high concentrations of FLC. This 
